{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:49:32Z","timestamp":1793170172304,"version":"4.5.0"},"reference-count":57,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.43955","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T18:19:01Z","timestamp":1642529941000},"page":"e2143955","source":"Crossref","is-referenced-by-count":150,"title":["Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials"],"prefix":"10.1001","volume":"5","author":[{"given":"Julia W.","family":"Haas","sequence":"first","affiliation":[{"name":"Program in Placebo Studies, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike L.","family":"Bender","sequence":"additional","affiliation":[{"name":"Department of Clinical Psychology and Psychotherapy, Philipps University Marburg, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ballou","sequence":"additional","affiliation":[{"name":"Program in Placebo Studies, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kelley","sequence":"additional","affiliation":[{"name":"Program in Placebo Studies, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Psychology, Endicott College, Beverly, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Wilhelm","sequence":"additional","affiliation":[{"name":"Department of Clinical Psychology and Psychotherapy, Philipps University Marburg, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin G.","family":"Miller","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Rief","sequence":"additional","affiliation":[{"name":"Department of Clinical Psychology and Psychotherapy, Philipps University Marburg, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted J.","family":"Kaptchuk","sequence":"additional","affiliation":[{"name":"Program in Placebo Studies, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"issue":"2","key":"zoi211215r2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s10900-020-00958-x","article-title":"COVID-19 vaccination hesitancy in the United States: a rapid national assessment.","volume":"46","author":"Khubchandani","year":"2021","journal-title":"J Community Health"},{"issue":"n1138","key":"zoi211215r3","doi-asserted-by":"crossref","first-page":"n1138","DOI":"10.1136\/bmj.n1138","article-title":"COVID-19 vaccination hesitancy.","volume":"373","author":"Razai","year":"2021","journal-title":"BMJ"},{"issue":"15","key":"zoi211215r4","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.vaccine.2021.02.005","article-title":"International estimates of intended uptake and refusal of COVID-19 vaccines: a rapid systematic review and meta-analysis of large nationally representative samples.","volume":"39","author":"Robinson","year":"2021","journal-title":"Vaccine"},{"key":"zoi211215r6","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2020.575950","article-title":"A proactive approach for managing COVID-19: the importance of understanding the motivational roots of vaccination hesitancy for SARS-CoV2.","volume":"11","author":"Taylor","year":"2020","journal-title":"Front Psychol"},{"issue":"27","key":"zoi211215r8","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1016\/j.vaccine.2020.04.029","article-title":"Why do parents not re-vaccinate their child for influenza? a prospective cohort study.","volume":"38","author":"Smith","year":"2020","journal-title":"Vaccine"},{"issue":"1","key":"zoi211215r9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170550","article-title":"Barriers of influenza vaccination intention and behavior\u2014a systematic review of influenza vaccine hesitancy, 2005-2016.","volume":"12","author":"Schmid","year":"2017","journal-title":"PLoS One"},{"issue":"44","key":"zoi211215r10","doi-asserted-by":"publisher","first-page":"7599","DOI":"10.1016\/j.vaccine.2011.07.130","article-title":"College students\u2019 perceptions of H1N1 flu risk and attitudes toward vaccination.","volume":"29","author":"Ramsey","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"zoi211215r11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.vaccine.2012.10.064","article-title":"Theory-based predictors of influenza vaccination among pregnant women.","volume":"31","author":"Gorman","year":"2012","journal-title":"Vaccine"},{"issue":"7","key":"zoi211215r12","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1080\/21645515.2019.1709351","article-title":"Seasonal influenza vaccine uptake among Chinese in Hong Kong: barriers, enablers and vaccination rates.","volume":"16","author":"Sun","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"zoi211215r13","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1186\/s13063-018-3042-4","article-title":"Rapid overview of systematic reviews of nocebo effects reported by patients taking placebos in clinical trials.","volume":"19","author":"Howick","year":"2018","journal-title":"Trials"},{"issue":"5","key":"zoi211215r14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1001\/jama.287.5.622","article-title":"Nonspecific medication side effects and the nocebo phenomenon.","volume":"287","author":"Barsky","year":"2002","journal-title":"JAMA"},{"issue":"4","key":"zoi211215r15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/pds.2067","article-title":"Assessing general side effects in clinical trials: reference data from the general population.","volume":"20","author":"Rief","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"zoi211215r16","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuroscience.2007.02.020","article-title":"When words are painful: unraveling the mechanisms of the nocebo effect.","volume":"147","author":"Benedetti","year":"2007","journal-title":"Neuroscience"},{"issue":"3","key":"zoi211215r17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.pain.2009.07.010","article-title":"A systematic review of adverse events in placebo groups of anti-migraine clinical trials.","volume":"146","author":"Amanzio","year":"2009","journal-title":"Pain"},{"issue":"11","key":"zoi211215r18","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2165\/11316580-000000000-00000","article-title":"Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis.","volume":"32","author":"Rief","year":"2009","journal-title":"Drug Saf"},{"key":"zoi211215r19","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3389\/fpsyt.2019.00504","article-title":"Minimizing drug adverse events by informing about the nocebo effect\u2014an experimental study.","volume":"10","author":"Pan","year":"2019","journal-title":"Front Psychiatry"},{"issue":"June","key":"zoi211215r20","article-title":"Improving medication tolerance: a pilot study in disorders of gut-brain interaction treated with tricyclic antidepressants.","author":"Ballou","year":"2021","journal-title":"J Clin Gastroenterol"},{"issue":"7","key":"zoi211215r21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/abm\/kay071","article-title":"The influence of side effect information framing on nocebo effects.","volume":"53","author":"Faasse","year":"2019","journal-title":"Ann Behav Med"},{"issue":"4","key":"zoi211215r22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s12529-018-9726-z","article-title":"Decreasing the burden of side effects through positive message framing: an experimental proof-of-concept study.","volume":"25","author":"Wilhelm","year":"2018","journal-title":"Int J Behav Med"},{"issue":"11","key":"zoi211215r23","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/S0895-4356(96)00177-1","article-title":"Framing effects on expectations, decisions, and side effects experienced: the case of influenza immunization.","volume":"49","author":"O\u2019Connor","year":"1996","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"zoi211215r24","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jaip.2019.01.022","article-title":"Changing patient mindsets about non-life-threatening symptoms during oral immunotherapy: a randomized clinical trial.","volume":"7","author":"Howe","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"zoi211215r25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.psychres.2013.10.019","article-title":"Nocebo in clinical trials for depression: a meta-analysis.","volume":"215","author":"Mitsikostas","year":"2014","journal-title":"Psychiatry Res"},{"issue":"46","key":"zoi211215r26","doi-asserted-by":"publisher","first-page":"12014","DOI":"10.1523\/JNEUROSCI.2947-06.2006","article-title":"The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect.","volume":"26","author":"Benedetti","year":"2006","journal-title":"J Neurosci"},{"key":"zoi211215r27","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3389\/fphar.2019.00502","article-title":"Are patients with schizophrenia spectrum disorders more prone to manifest nocebo-like-effects? a meta-analysis of adverse events in placebo groups of double-blind antipsychotic trials.","volume":"10","author":"Palermo","year":"2019","journal-title":"Front Pharmacol"},{"issue":"7","key":"zoi211215r28","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/pds.v26.7","article-title":"Types, frequencies, and burden of nonspecific adverse events of drugs: analysis of randomized placebo-controlled clinical trials.","volume":"26","author":"Mahr","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"zoi211215r30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/17512433.2021.1900728","article-title":"How do nocebo effects in placebo groups of randomized controlled trials provide a possible explicative framework for the COVID-19 pandemic?","volume":"14","author":"Amanzio","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"n71","key":"zoi211215r32","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"zoi211215r33","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"11","key":"zoi211215r36","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"2","key":"zoi211215r37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis.","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"issue":"5","key":"zoi211215r38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.","volume":"384","author":"Baden","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"zoi211215r39","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 COVID-19 vaccine.","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"issue":"25","key":"zoi211215r40","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates.","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"10275","key":"zoi211215r41","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","article-title":"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.","volume":"397","author":"Richmond","year":"2021","journal-title":"Lancet"},{"issue":"19","key":"zoi211215r42","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine.","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi211215r43","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.vaccine.2021.02.007","article-title":"A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.","volume":"39","author":"Chu","year":"2021","journal-title":"Vaccine"},{"issue":"24","key":"zoi211215r44","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine.","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi211215r45","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/s41591-021-01330-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.","volume":"27","author":"Li","year":"2021","journal-title":"Nat Med"},{"issue":"9","key":"zoi211215r46","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S1473-3099(21)00147-X","article-title":"Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.","volume":"21","author":"Goepfert","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"20","key":"zoi211215r47","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant.","volume":"384","author":"Madhi","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"zoi211215r48","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine.","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi211215r49","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","article-title":"Efficacy of NVX-CoV2373 COVID-19 vaccine against the B.1.351 variant.","volume":"384","author":"Shinde","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi211215r50","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S1473-3099(21)00200-0","article-title":"Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.","volume":"21","author":"Chappell","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"zoi211215r51","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/j.pain.2012.09.007","article-title":"The hidden effects of blinded, placebo-controlled randomized trials: an experimental investigation.","volume":"153","author":"Rief","year":"2012","journal-title":"Pain"},{"issue":"13","key":"zoi211215r55","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1056\/NEJM196809262791304","article-title":"Adverse nondrug reactions.","volume":"279","author":"Reidenberg","year":"1968","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi211215r56","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/15265161.2011.652798","article-title":"To tell the truth, the whole truth, may do patients harm: the problem of the nocebo effect for informed consent.","volume":"12","author":"Wells","year":"2012","journal-title":"Am J Bioeth"},{"key":"zoi211215r29","author":"Bender","year":"2021"},{"key":"zoi211215r31","author":"Rief","year":"2021"},{"key":"zoi211215r1","doi-asserted-by":"crossref","unstructured":"World Health Organisation. WHO coronavirus (COVID-19) dashboard. 2021. Accessed November 10, 2021. https:\/\/covid19.who.int\/","DOI":"10.46945\/bpj.10.1.03.01"},{"key":"zoi211215r5","unstructured":"World Health Organization. Ten threats to global health in 2019. Accessed September 1, 2021. https:\/\/www.who.int\/news-room\/spotlight\/ten-threats-to-global-health-in-2019"},{"key":"zoi211215r7","unstructured":"Imperial College London. COVID-19: global attitudes towards a COVID-19 vaccine. Accessed June 21, 2021. https:\/\/www.imperial.ac.uk\/media\/imperial-college\/institute-of-global-health-innovation\/GlobalVaccineInsights_ICL-Covid-19-Behaviour-Tracker-EMBARGOED-00.01-04.02.2021.pdf"},{"key":"zoi211215r34","unstructured":"Microsoft Excel. Microsoft Corporation; 2018. Accessed August 16, 2019. https:\/\/office.microsoft.com\/excel"},{"key":"zoi211215r35","unstructured":"JASP. Version 0.14.1. JASP; 2020. Accessed May 21, 2021. https:\/\/jasp-stats.org\/download\/"},{"key":"zoi211215r52","unstructured":"Centers for Disease Control and Prevention. Moderna COVID-19 vaccine overview and safety. Updated November 19, 2021. Accessed August 16, 2021. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/different-vaccines\/Moderna.html"},{"key":"zoi211215r53","unstructured":"Centers for Disease Control and Prevention. Pfizer-BioNTech COVID-19 vaccine (also known as COMIRNATY) overview and safety. Updated November 19, 2021. Accessed August 16, 2021. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/different-vaccines\/Pfizer-BioNTech.html"},{"key":"zoi211215r54","unstructured":"Centers for Disease Control and Prevention. Johnson & Johnson\u2019s Janssen COVID-19 vaccine overview and safety. Updated October 29, 2021. Accessed August 16, 2021. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/different-vaccines\/janssen.html"},{"key":"zoi211215r57","unstructured":"Rief? W, Glombiewski? JA, Barsky? AJ. Generic assessment of side effects. 2009. Accessed June 21, 2021. http:\/\/www.gase-scale.com\/Instruction_GASE.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2788172\/haas_2022_oi_211215_1644253897.77143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T16:00:28Z","timestamp":1644595228000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2788172"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.43955","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]}}}